Headache
-
New treatments are needed to treat chronic daily headache (CDH) and chronic cluster headache (CCH). New treatments are needed to treat this population and intravenous (IV) lidocaine is a novel treatment for CDH. ⋯ This study suggests benefit of lidocaine treatment and the need for further prospective analyses. The mechanism of lidocaine in treating headache is unknown.
-
Randomized Controlled Trial
Evaluation of carisbamate for the treatment of migraine in a randomized, double-blind trial.
This study explored the dose-response relationship of carisbamate administered at doses of 100 mg per day, 300 mg per day, or 600 mg per day, in the prevention of migraine. ⋯ Carisbamate was not more efficacious in migraine prophylaxis than placebo in this well-controlled study that included a suitable population. However, carisbamate monotherapy was well tolerated at doses up to 600 mg per day.
-
Case Reports
Intravenous lidocaine infusion for the treatment of post-acoustic neuroma resection headache: a case report.
Presentation of a case report of a 47-year-old male with a post-acoustic neuroma resection intractable headache responding to intravenous lidocaine infusion. The patient was then switched to mexiletine, with good response.
-
Few studies in adolescents deal with the level of agreement between questionnaire and interview information in relation to headache symptoms. ⋯ The results indicate that our self-administered questionnaire may be an acceptable instrument in determining the prevalence of migraine sufferers in the northeast Italy adolescent population, useful in identifying subjects with "definite" migraine.
-
Despite the high level of individual and societal burden resulting from headache disorders, the National Institutes of Health (NIH) has funded relatively little research on these disorders. ⋯ A small number of research grants on headache disorders were funded by the NIH over the last 2 decades, with 2007 funding estimated between $6.8 and $13 million. By comparison to NIH funding of research on 10 chronic medical conditions relative to disease burden, headache research funding should exceed $103 million annually.